TRIBE2: Latest data for patients with mCRC

Bookmark and Share
Published: 15 Jul 2019
Views: 414
Rating:
Save
Dr Chiara Cremolini - Università di Pisa, Pisa, Italy

Dr Chiara Cremolini speaks to ecancer at ESMO 21st World Congress on Gastrointestinal Cancer about the TRIBE2 updated results.

She reports that the trial met its primary endpoint of prolonged second progression-free survival in the arm of unresectable metastatic colorectal cancer (mCRC) patients treated with upfront FOLFOXIRI plus bevacizumab followed by the pre-planned reintroduction of the same agents after disease progression.

Dr Cremolini outlines how the toxicity profiles varied and what these latest results mean for clinical practice in the future.